Malignant melanoma is the most deadly form of skin cancer and is difficult to treat successfully once it has spread to other organs. The BRAF gene is faulty in about half of malignant melanomas and many other cancers, making it a suitable drug target. Drugs that block BRAF function in cells are already showing positive results in early clinical trials in melanoma patients in the US.
About half of the melanomas that do not have faults in BRAF have errors in a different protein called RAS. In this study, scientists examined the effect of drugs that block BRAF function on the melanomas with faulty RAS. They found that the drugs caused an unexpected activation of the processes that drive cancer cell growth. So one of the consequences of giving these drugs to patients with a faulty RAS gene is that the drug could encourage the melanoma to grow, rather than slow down.
Lead author Professor Richard Marais, a Cancer Research UK-funded scientist from The Institute of Cancer Research, said: “These unexpected findings give us much more insight into how BRAF drugs will behave in humans. These are preliminary laboratory findings, but they strongly suggest that BRAF drugs should not be given to patients who have faults in the RAS gene, because long-term use could accelerate tumour growth.
“This study highlights the importance of understanding the genetics of cancer to achieve therapeutic benefit. It will enable clinicians to select which patients they administer these drugs to, allowing them to personalise treatment for each patient. This research also provides the springboard for developing drugs that will work in patients whose tumours carry a faulty RAS gene.”
Dr Lesley Walker, director of cancer information at Cancer Research UK, said: “These findings provide an important insight into the genetic mechanisms of human cancer. They show how basic scientific research is vital to clinical care and emphasise the importance of understanding the makeup of individual cancers when using new targeted treatments of this type.
“The impact of this research will enable doctors’ testing BRAF inhibitors in the clinic to target the treatments more precisely to patients who will definitely benefit, and avoid treating those who won’t.”
For more information, contact Emma Gilgunn-Jones in the Cancer Research UK press office on 0207 061 8311, or out-of-hours the duty press officer on 07050 264 059.
- Heidorn, S. et al (2010). Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF Cell, 140 (2), 209-221 DOI: 10.1016/j.cell.2009.12.040
Notes to editors
About malignant melanoma
Around 10,400 cases of malignant melanoma are diagnosed in the UK each year, and 2,000 people die from the disease. Malignant melanoma incidence rates in Britain have more than quadrupled since the 1970s.
There are two main types of skin cancer: non-melanoma skin cancer, which is very common, and malignant melanoma which is less common but more serious.
Registration of non-melanoma skin cancer is incomplete. Around 82,000 cases of non-melanoma skin cancer are registered but it is estimated that the actual number is at least 100,000 cases in the UK each year.
For more information about skin cancer and treatments, visit Cancer Research UK’s patient information website CancerHelp UK
To search for BRAF inhibitor trials in the US, visit the clinical trials website for the US National Institutes of Health